UniQure stock doubles after FDA meeting on Huntington's disease
Dutch-based uniQure saw its stock {$QURE} rise by more than 120% on Tuesday after it disclosed that it is "in alignment" with the FDA on using the accelerated approval pathway for its experimental...
View ArticleNewAmsterdam hits primary endpoint in CETP inhibitor trial
NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of lipoprotein that carries cholesterol in the blood. The BROADWAY trial hit on ...
View Article#ASH24: Early data on BTK degraders suggest promise of next-gen approach
SAN DIEGO — Drug developers are making a new generation of treatments for blood cancers that arise from abnormal B cells by taking advantage of the body’s natural protein recycling system. BeiGene
View ArticleContending with Americans’ fury at health insurers
Since last week's shooting and death of UnitedHealthcare CEO Brian Thompson, there's been a wave of frustration expressed with the health insurance industry, and support for the alleged killer. The...
View ArticleBayer exits Europe pact with Moberg for nail fungus drug after Phase 3 fail
Moberg Pharma’s Terclara has flunked a late-stage test evaluating less frequent maintenance dosing for fungal nail infection, prompting Bayer to pull out of planned launch activities in Europe and...
View ArticleNegev Labs debuts with $30M in assets, striving to build a network of...
A new psychedelic-focused startup incubator is debuting, backed by an investor behind some of the most prominent biotechs in the space. The main theme of the companies it wants to build? No tripping....
View ArticleExclusive: Angitia, a Bain-backed musculoskeletal biotech, raises $120M for...
Angitia Biopharmaceuticals, a California and China biotech developing musculoskeletal biologics, has closed a $120 million Series C led by Bain Capital Life Sciences, the drug developer exclusively...
View ArticleGenetic medicine startups Chroma, Nvelop merge into nChroma
What started as two CEOs eating tacos and talking biotech led to a merger and a new company. The epigenetic editing startup Chroma Medicine and the delivery specialist Nvelop Therapeutics said...
View ArticleThe Endpoints 100 Survey: Biotech industry braces for Trump 2.0
Big changes are afoot at the FDA in the wake of Donald Trump’s reelection, and there’s considerable anxiety in senior biotech ranks that an upheaval in the agency could trigger both an exodus of...
View Article#SABCS24: Lilly’s oral SERD makes strides in breast cancer with Phase 3 data
Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or death among patients with mutated estrogen receptor genes, but not in all...
View ArticleAcelyrin says goodbye to the drug that got it a $540M IPO in 2023
Acelyrin is officially ending development of an experimental medicine it referred to as a "diamond in the rough" and that served as the foundation for one of the
View Article#ASH24: Gene editing companies seek safer, less grueling conditioning methods...
SAN DIEGO — New and experimental gene therapies made with blood stem cells rely on the same grueling, decades-old methods for a process called conditioning that’s used for bone marrow transplants. It’s...
View ArticleBenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal
Plus, news about NewAmsterdam, Rocket, ImmunityBio, CG Oncology, Spruce Biosciences, Pharming, Veradermics, Noema Pharma, Ambrosia Biosciences, EsoBiotec, Cellectar Biosciences and Hepion:...
View ArticleRelay Therapeutics plans pivotal trial in second-line breast cancer for 2025
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα inhibitor in breast cancer. In the Phase 1/2 trial, 64 patients with...
View ArticlePost-Hoc: What insurance CEO's killing says about US health anger
Years ago when I was visiting Arizona, Congresswoman Gabby Giffords was shot in the head. Giffords had been greeting constituents at a Tucson shopping mall, and I was riding my bike by the complex as ...
View ArticleCandel soars on prostate cancer data despite unclear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending its share price {$CADL} up around 60% even as the same treatment flunked a...
View ArticleNIH halts enrollment in trial for SIGA's mpox antiviral after disappointing data
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National Institute of Allergy and Infectious Diseases announced this week. SIGA’s...
View ArticleDrugs are approved and available faster in US than most of EU, data show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA Institute for Human Data Science. The difference can be attributed in part ...
View Article